SNCA and Parkinson disease: Another vaccination-based approach consisted of administrating short fragments of α-synuclein conjugated to a carrier, also known as the AFFITOPE® AFF1 vaccine, which resulted in the stimulation of antibodies against the C-terminal part of α-synuclein in two mouse models of PD [105].